Nasal Infections in Cystic Fibrosis Patients – Pilot Study

Evaluation of Cytokine IL-22 Levels in Nasal Secretions of Pediatric Cystic Fibrosis Patients

Protocol Description

Through this study, researchers are collecting nasal secretion samples from patients with cystic fibrosis (CF) to see they contain signs of immune activation. Lung infections, which are common in CF patients, activate the immune system and can damage the lungs. Investigators believe there may be a relationship between lung infections and infections that may start in the nose.

Study Level: Pilot

Eligibility Criteria

Subject to exclusion criteria, the study is accepting individuals of both genders, ages 1 month to 21 years, who are diagnosed with CF and being treated at Children’s Hospital of Pittsburgh of UPMC for nasal secretions.
Males and Females: Ages 1 month to 21 years


The patient’s physician is involved as an investigator in this study and will suction secretions from the patient’s nose, as would normally be done for treatment. Collected samples will be sent for analysis.
Visits: None beyond clinical care for the condition
Duration: Up to 2 years

Status: Open to Enrollment

Source(s) of Support

National Institutes of Health

Additional Information

Otolaryngology (ENT) Research

Primary Investigator

Amanda Stapleton, MD

Contact Information

For more information about the study or enrollment, please contact:
Amber Shaffer, PhD, Research Coordinator